Product Number: F044127
English Name: Finerenone Impurity 127
English Alias: ethyl 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate
CAS Number: 2764833-07-8
Molecular Formula: C₂₃H₂₅N₃O₄
Molecular Weight: 407.46
As an impurity of Finerenone, this compound has the following advantages:
Well-defined with distinct functional groups: Contains 1,6-naphthyridine core, 4-(4-cyano-2-methoxyphenyl) substituent, 5-ethoxy, 2,8-dimethyl, and 3-ethyl carboxylate. Unlike finerenone (mineralocorticoid receptor antagonist), its cyano polarity, ether hydrophobicity, and conjugated naphthyridine create significant physicochemical differences, enabling precise differentiation via HPLC/SFC as a specific marker;
High stability and traceability: Rigid naphthyridine structure and stability of cyano/ether/ester groups ensure neutral-to-weakly-acidic stability. As a byproduct from incomplete cyclization or substituent deviation in finerenone synthesis, it directly reflects key step efficiency, improving process tracing accuracy;
High detection sensitivity: Conjugated naphthyridine-benzene shows strong UV absorption (250-300nm), combined with m/z 408 [M+H]⁺ enabling ppb-level analysis via LC-MS, compatible with naphthyridine drug impurity systems.
Pharmaceutical quality control: Used as an impurity reference standard to quantify Finerenone Impurity 127 in APIs, ensuring compliance with specific impurity limits in quality standards;
Synthesis optimization: Optimizing cyclization conditions (catalyst dosage) by monitoring impurity levels to reduce byproducts and enhance target specificity;
Method validation: Verifying accuracy and specificity of finerenone impurity assays to ensure effective separation and quantification.
Finerenone’s structure is based on a 1,6-naphthyridine core, synthesized via multi-step substitution and cyclization. Deviations in substituent position/type (e.g., ethoxy misplacement) may generate analogs like Finerenone Impurity 127. Due to structural similarity affecting receptor binding, its residues impact finerenone quality and safety, making control critical for assurance.
Current research focuses on:
Analytical method validation: Developing UPLC assays with C18 columns for baseline separation, achieving 0.05 ppb detection limits;
Synthesis kinetics: Studying impurity formation under varying cyclization reagents to clarify substituent-cyclization efficiency correlation;
Control strategies: Optimizing intermediate purity to keep impurity levels below 0.1% and enhance API quality;
Structural confirmation: Using ¹H/¹³C-NMR and MS/MS to verify substituent positions, distinguishing from finerenone for authoritative identification.
China
